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FOREWORD

Phenylketonuria (phenylpyruvic oligophrenia) and branched-chain ketonuria (maple syrup urine disease) are inborn
errors of essential amino acid metabolism.

Phenylketonuria

was first observed by Falling in 193** and branched-chain
ketonuria was described by Menkes, Hurst, and Craig in 195**.
Both disorders share common features which suggest that they
may have a common biochemical etiology while the genetic
defects are dissimilar autosomal recessive traits.

In each

case, no prenatal damage has been detected, but following
birth, the clinical symptoms become apparent.

The major

clinical features shared by phenylketonuria and branchedchain ketonuria are muscular hypertonicity, vomiting, con
vulsive seizures, mental retardation, and premature death.
The symptoms of phenylketonuria are less severe than those of
branched-chain ketonuria while the incidence of phenylketon
uria is higher than that of branched-chain ketonuria.

The

occurence of phenylketonuria has been estimated to be one
case in 25,000 births and that of branched-chain ketonuria to
be one in 250,000 births.

Both disorders are pan-ethnic,

with the reported incidence higher in technologically advanc
ed areas due to the increased ability to diagnose them.

The

incidence of phenylketonuria and branched-chain ketonuria, as
well as other recessive genetic defects, is at least ten
times higher in the region of Louisiana known as Acadiana.

This has been attributed to the geographic isolation of the
Acadians from the early l 600*s to the late 1800*s and the
subsequent consanguinity of the marriages.
The onset of clinical manifestations in phenylketonuria
is delayed for one to two months postpartum.

By the end of

the first year, the undiagnosed patient is transformed from
an apparently normal baby into a quite retarded one.

In

addition to the features common to branched-chain ketonuria
patients, phenylketonuria patients make no attempts to walk
or talk.

They are also hyperkinetic and microcephalic.

Estimated intelligence quotients for untreated phenylketonurics from ages 3 to 9 are 30 to *f0.

Electroencephalograph

abnormalities suggest deep midline brain damage.

Three-

quarters of phenylketonurics die by age 30 from infectious
diseases (i.e., pneumonia, tuberculosis, and nephritis).
The appearance of symptoms in branched-chain ketonuria
occurs during the first week following birth.

The suckling

response is lost and the urine acquires an odor character
istic of maple syrup or burned sugar.

The hypertonicity,

vomiting and seizures common to phenylketonuria are evident
along with apnea and lethargy.

Death usually occurs in the

first year and survival past the second year is rare.

While

many of the symptoms are similar to phenylketonuria, their
onset is much more rapid and acute.

Severe mental retarda

tion is always manifest when the branched-chain ketonuria
patient survives for a period sufficiently long enough
iv

to measure mental development.
Phenylalanine hydroxylase is a liver enzyme that is
part of a dihydrobiopterine dependent hydroxylating system
that is also considered to be responsible for the hydroxylation of tyrosine and tryptophan.

In

phenylketonuria,

an inactive phenylalanine hydroxylase is produced by the
defective gene and precludes the conversion of phenylalanine
to tyrosine.

As a result, the phenylalanine metabolites

accumulate from the alternate routes of phenylalanine
metabolism.

Phenylalanine and its metabolites are elevated

in the plasma along with several tryptophan metabolites.
Branched-chain ketonuria results from the defective
catabolism of the branched-chain amino acids, leucine, iso
leucine, and valine.

They are transaminated normally to

their correspnding a-ketoacids, but the oxidative decarboxy
lation to the acyl-Coenzyme A derivatives is blocked.

The

branched-chain a-ketoacids, are normally metabolized in the
liver and to a minor degree in the kidney.

The decarboxy

lation of the branched-chain a-ketoacids (BCKA) is catalyzed
by a multienzyme dehydrogenase system similar to the multi
enzyme complexes involved in pyruvate and a-ketoglutarate
decarboxylation.

It has not

yet been resolved whether

there are one or more BCKA dehydrogenase complexes affected
in the diseased state.

As result of the interrupted BCKA

metabolism the branched-chain amino acids and their a-keto
acids accumulate in abnormally high levels in the plasma
v

along with indoleacetic acid.
In both disorders! it is accepted that the elevated
metabolite levels adversely affect normal biochemical
systems.

The major systems affected are energy metabolism,

transport, and biosynthesis of proteins, lipids, neuro
transmitters, and myelin.

In general, the abnormally high

a-ketoacid levels in phenylketonuria and branched-chain
ketonuria are considered to elicit the similar clinical
symptoms by affecting many of the same biochemical processes.
This report will elaborate on the effects of the branchedchain ketonuria and phenylketonuria metabolites on a part
icular aspect of the disruption of energy metabolism.

The

results will be discussed in relation to the proposed common
etiology of the disorders found in phenylketonuria and
branched-chain ketonuria.
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ABSTRACT

Branched-chain ketonuria (BCKU) and phenylketonuria
(PKU) are inborn errors of amino acid metabolism resulting
in mental retardation and premature death.

BCKU is due to

the genetic inability to sythesize a functional branchedchain a-ketoacid dehydrogenase to oxidatively decarboxylate
the a-ketoacids of leucine, isoleucine, and valine trans
aminations.

The genetic defect in PKU is the synthesis of a

mutant phenylalanine hydroxylase incapable of oxidizing
phenylalanine to tyrosine.

In both disorders the amino

acids and their corresponding a-ketoacids accumulate in the
serum to high levels (10 m M ) ,

The most offensive metabo

lites are a-ketoisocaproate (KIC) in BCKU and phenylpyruvate
(PPA) in PKU.

The reduced postpartum myelination leading to

retardation is thought to be due to the lack of necessary
precursors and defective energy metabolism.
Demonstration of a pyruvate transport system and the
subsequent

reports that this system was inhibited by PPA

and KIC were taken as the explanation of the depressed
energy metabolism.

PPA and KIC were soon shown not to be

as effective pyruvate transport inhibitors as originally
reported.

Electron micrographs showing disruption of mito

chondrial integrity in the presence of 0,1 mM PPA or KIC
suggested that the disease metabolites exerted their effects
through perturbations of membraneous energy transducing
*

X I

*

1

systems.
To test this possibility, a study of the effects of the
BCKU and PKU a-ketoacids on the respiration parameters of
the succinate oxidase system in mouse liver mitochondria was
undertaken.

This system was chosen since it is an integral

membrane enzyme associated with the electron transport sys
tem and disturbances in its membraneous environment could
be detected through changes in its respiratory parameters.
The oxidation of 7*5 mM succinate was monitored with a
Clark oxygen electrode at 37° C and pH 7.^.

The a-ketoacids

were added to a final concentration of 7.5 mM,

PPA reduced

the State 3 oxidation rates 10-20$ while KIC had no effect.
The State k rates were increased 10-30$ by KIC and 20-^7$
by PPA.

The acceptor control ratios (ACR) were reduced 8-

23$ by KIC and 23-^5$ toy PPA.
6-10$ by KIC and 12-20$ by PPA.

The ADP/0 ratios were reduced
The reduction of the ACR

was found to be concentration dependent.

Reduction of the

ACR by PPA was detected at levels below 1 mM, while the KIC
effect was observed at 2.5 mM.
The increase in the State k oxidation rates and the
decreases in the ACR's and the ADP/0 ratios indicate that
PPA and KIC are partially uncoupling succinate oxidation
from ADP phosphorylation.

The decrease of State 3 oxi

dation by PPA indicates that it is an electron transport
inhibitor.

These findings are supportive of the observation

that PPA and KIC are perturbing mitochondrial structure.
xiii

In doing so, these compounds reduce the efficiency of oxi
dative phosphorylation and the result is a decrease of ATP
available for biosynthesis in the rapidly developing new
born afflicted with PKU or BCKU.

This partial uncoupling of

oxidative phosphorylation and the concomitant inhibition of
other enzyme systems by PPA and KIC could produce a general
depression of energy metabolism in the neonate that would
impair the myelination process and result in permanent
mental retardation.
It is apparent from these results and those from other
laboratories that there is no single biochemical phenomenon
responsible for the mental retardation and other symptoms
of PKU and BCKU.

It appears that these genetic disorders

produce their similar devastating abnormalities through an
accumulation of many small effects due to the reduction in
the effiency in energy production and the inhibition of the
biosynthesis of the necessary developmental metabolites.

INTRODUCTION

Branched-chain ketonuria (BCKU) (see Appendix 1 for
abbreviations used) and phenylketonuria (PKU) are the result
of inherited disorders in essential amino acid metabolism
(1 ,2 ,3 ).

In each case, the normal metabolism is blocked due

to a genetically defective enzyme system.

The oxidation of

phenylalanine to tyrosine by phenylalanine hydroxylase is
the specific metabolic disorder in PKU,

The loss of this

enzymatic reaction leads to the accumulation of phenyl
alanine metabolites by the alternate pathways shown in
Figure 1.

Less than 50# of the excess phenylalanine is

incorporated into protein, leaving the remainder to be con
verted to phenyl ethyl amine (PEA), phenylpyruvic acid (PPA.),
phenyllactic acid (PLA), o-hydroxyphenyllactic acid (HPLA),
and phenylacetic acid (PAA).

The aberrant biochemical event

in BCKU is the oxidative decarboxylation of the a-keto ana
logs of the branched-chain amino acids.

As shown in Figure

2 , there is normal transamination of leucine, isoleucine,
and valine to their branched-chain a-ketoacids (BCKA).

The

defective BCKA dehydrogenase(s) prevent the decarboxylation
and the subsequent formation of the respective acyl-Coenzyme
A derivatives.

As in PKU, the BCKU metabolites, leucine,

valine, isoleucine, alloisoleucine, a-ketoisocaproic
acid (KIC), a-ketoisovaleric acid (KIV),

and a-keto-P-

methylvaleric acid (KMV), accumulate to abnormally high

2
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Figure 1. Phenylalanine Metabolism Showing the Reaction
Blocked in PKU.
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levels in blood and urine.
A comparison of the PKU and BCKU metabolites with some
intermediates of the citric acid cycle show that they share
the a-ketoacid structure as seen in Figure 3*

This similar

ity in structure suggests that the disease metabolites
possess the potential for acting as alternate substrates,
substrate analogs, or even inhibitors of the energy related
reactions involving pyruvate, a-ketoglutarate, and oxaloacetate.

The merit of this suggestion is demonstrated in

Table 1 which is a compilation

of the metabolic systems

whose normal function is adversely affected by the metabo
lites of BCKU and PKU.

A large number of processes or

enzymes listed are directly or indirectly involved in the
production of energy.

The majority of the remaining systems

utilize the energy produced by the other reactions.

It is

immediately obvious that if the energy production machinery
of the cell is depressed, the systems which utilize that
energy will also be depressed.

Of all the systems listed

in Table 1, over half of them are affected by the PKU and
BCKU metabolites.

Those systems that are not listed as

being affected by the metabolites of both disorders have
generally not been tested for deleterious effects by the
toxic compounds produced in each disease.

Of the 23 systems

listed in Table 1 that are affected by the metabolites of
both diseases, about two thirds of them can be directly or
indirectly related to cellular energy production.

The

remaining commonly affected processes may be regarded as

5
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Figure 3»

Structural Analogy of the PKU and BCKU Metabolites

with Certain Energy Metabolites and a-Cyano-A-hydroxycinnamic Acid.

TABLE 1
Metabolic Systems Affected by Phenylketonuria and Branched-Chain Ketonuria Metabolites.*
Process or Enzyme
Affected ^

Tissue
or M
Svstenr^

Phenylketonuria
Metabolite(s )##

Ref.

Acetoacetate Oxidation

B

PPA

58

Acetoacetyl-CoA Thiolase

B

Phe,PPA

UrJ

Acetyl-CoA Carboxylase

B

PPA

24

Acetylcholinesterase

B

Acetylcholine Synthesis

B

Phe, PPA

Amino Acid Transport

B,H

Phe,PPA

8,56,

Branched-Chain Ketonuris
Metabolite (s

Ref.

KIC

58

Leu

8

KIC,KMV,KIV

44

Leu,Val,Ile

8,56

KIC,KMV,KIV,Leu

26,48

KIC.KMV

29

KIC,KMV,KIV

29,44

6o
Cell Growth

Fb.Lb

Citrate Synthase

B

PPA

24

DOPA Decarboxylase

A

PPA,PLA,PAA

5

Fatty Acid Synthetase

B

PPA

24

K,L

PPA

53,5k>

B

PPA

7

KIC,KIV

7

Phe, PPA

16,30

KIC,KIV,KMV,
Leu, Ile,Val

44

Gluconeogenesis
Glutamate Decarboxylase
Glycolysis

B,L

TABLE 1 (continued)
Hexokinase

B

PPA

13

3-Hydroxybutyrat e Dehydrogenase

B

PPA,PAA,PLA

43

PEA.HPAA
3-Hydroxybutyrate Oxidation

B

PPA,PHE,PAA
PEA,PLA,HPAA

51

32,45

3-Hydroxybutyrate Transport

B

PPA

45

5-Hydroxytryptophan Decarboxylase

K

PPA,PLA,PAA

6

Insulin Release

P

Ketone Body Levels
aKG Decarboxylation

L,B1
L,B

KIC

32,45

KIC

45

Leu,KIC

59

**

51

**

1,3

PPA

44,4?
49

KIC,KMV,KIV

14,34,
44,47,

49
aKG Oxidation

L,K,
H ,B

Lactate Dehydrogenase

L,B,M

Lipid Synthesis

B,L

KIC, KIV
PPA

21,51

Phe,PPA

2,4,
KIC,KMV,KIV
10,16
21,22 ,
27,35,
49

Leu

15
8
1,4,
21,44,

49

TABLE 1 (continued)
Malate Dehydrogenase

L

PPA

51

Mitochondrial Structure

B

PPA

36,37

KIC

36,37

Myelination

B

Phe

2,3,4,
10,49

KIC

1 ,3 ,
4,12,
49

Nucleic Acid Synthesis

B

PPA

16

KIC,KMV,KIV

44

3-0xoacid CoA Transferase

B

PPA ,HPAA ,PLA

Oxygen Consumption

B

PPA, PAA

9

KIC,KIV

9

6-Phosphogluconate Dehydrogenase

B,L

PPA

16

Protein Synthesis

B

Phe,PPA

8,16,
52

Leu,lie,KIC,
KMV,KIV

8,44

Pyruvate Carboxylase

B,L

PPA

20,42,
47

Pyruvate Decarboxylation

B,L

PPA

18,23

KIC,KIV,KMV

14,17,
19,25,
28,29,
44

Pyruvate Kinase

B,L

Phe

13,30,
44

KIC,KMV,KIV

44

Pyruvate Oxidation

L,H,
B,M

PPA

11,29, KIC,KIV
31.32,
45,46

43

15,29,
31.32,
45,69
CO

TABLE 1 (continued)
Pyruvate Transport

L,B,
E,H

Serotonin Levels

B1

Stearyl CoA Desaturase
Transaminati on

B

PPA

Phe.PPA.PAA,
PLA

31.38,
45,46,
55,57,
71

KIC,KIV

3

Leu

41
Leu,KIC,KIV

B,L

31,38,
40,45,
55,69,
71

33

* These are systems in which effects have been observed. The absence of an enzyme or
system from this compilation implies that there is no effect or it has not been examined.
** Where no metabolite is given, the effect was observed in the diseased state or an
animal model.
The process or enzyme activity was diminished except in the case of insulin release
which was increased.
# # Abbreviations:

A
B
B1 E
Fb H
HPAAHe K
KIC KIV -

adrenal
brain
blood
erythrocyte
fibroblast
heart
o-hydroxyphenylacetic acid
isoleucine
kidney
a-ketoisocaproic acid
a-ketoisovaleric acid

KMV
L
Lb
Leu
P
PAA
PEA
Phe
PLA
PPA
Val

-

a-keto-0-methylvaleric acid
liver
lymphoblast
leucine
pancreas
phenylacetic acid
phenylethylamine
phenylalanine
phenyllactic acid
phenylpyruvic acid
valine
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energy-requiring, biosynthetic transformations.

Those

biochemical systems that are not affected by the metabolites
of both diseased conditions also may be classified as
either biosynthetic or energy-generating.

In general, the

metabolites of PKU and BCKU depress energy metabolism and
in so doing, reduce the normal functioning of developmental
and biosynthetic pathways.
Most of the major clinical symptoms common to BCKU and
PKU, hypertonicity, ketosis, seizures and coma, are revers
ible through dietary therapy (1 ,2 ,3 ,8 ).

The mental retard

ation is not reversible and is thought to be due to the
depressed myelination observed in the brains and nervous
tissue of BCKU and PKU patients (4 ).

Myelination is the

process by which Schwann cells or oligodendrocytes form
the spirally arranged "insulating" sheath around peripheral
and central nervous tissue.

The process occurs primarily

during postpartum development.

The major portion of the

myelin sheath is composed of a proteolipid matrix formed
from hydrophobic proteins and complex lipids.

The defective

myelination observed (1 ,2 ,3 ,4 ,1 0 ,1 2 , 4 9 ) may be directly
attributed to the reduced lipid synthesis (1 ,2 ,4 ,1 0 ,1 6 ,2 1 ,
2 2 ,2 7 ,3 5 i 4 4 ,4-9 ) and protein synthesis (8 ,1 6 ,4 4 ,5 2 ).

An

indirect contributing factor could also be the decreased
energy metabolism as outlined in Table 1.
The suggestion that the irreversible neurological
defects in PKU and BCKU were due to the inhibition of
brain respiration during the developmental stages by the

11
elevated levels of PPA, KIC, KMV, and KIV was first develop
ed by Tashian in 1961 (7)*

Following Tashian*s suggestion,

reports of disruption of energy metabolism by BCKU and PKU
metabolites began to appear.

Oxygen consumption in brain

slices was lowered by 10 to 20# (9 ).

Using manometric

techniques, Gallagher showed that pyruvate oxidation in
brain mitochondria was inhibited by PPA (11).

A series

of reports by Bowden and his colleagues demonstrated that
PPA and KIC competitively inhibited the oxidative decarbox
ylation of pyruvate and a-ketoglutarate decarboxylation in
isotonic brain and liver homogenates (1^, 17 ,18 ,19 ,21,28).
KIC and KIV were shown to inhibit pyruvate and a- ketoglutarate oxidation in brain mitochondria (15 )•

It was also

reported that a-ketoglutarate dehydrogenase activity was
inhibited in a non-competitive fashion by KIC in sonicated
rat heart mitochondria (15)•

Land and Clark reported that

pyruvate dehydrogenase activity from thrice frozen and
thawed rat brain mitochondria were not affected by PPA (23,
75)•

The apparent contradiction to previous evidence by

Land and Clark (23) and Lysiak et al. (15) may be explained
by the demonstration that repeated freezing and thawing in
activates a-ketoglutarate dehydrogenase by degrading
phospholipids required for its activity

(6l).

the

Since

a-ketoglutarate dehydrogenase and pyruvate dehydrogenase
are similar multienzyme complexes(62) and sonication also
decomposes phospholipids (62), either of these treatments
could affect the enzymatic activities of these two similar
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multienzyme complexes from the mitochondrial matrix.

Other

reports have also shown the a-ketoacids of both diseases
inhibit a-ketoglutarate and pyruvate decarboxylation (25,
29,34,44,47,63,6*0 •

In those studies where the type of

inhibition was determined, it was found to be competitive
(29,34,47163164)■

From these studies it can be seen that

the PKU and BCKU a-ketoacids are detrimental to two pivotal
processes in oxidative energy metabolism.
The first indication that anaerobic energy metabolism
was affected was Appel's report that leucine inhibited
lactate dehydrogenase (8).

There have been subsequent

observations of the inhibition of lactate dehydrogenase
by PPA (21,51)*

Weber has reported that phenylalanine is

a competitive inhibitor of pyruvate kinase and that PPA
is an inhibitor of hexokinase (13)*

Weber and his col

leagues have also shown that the conversion of triosephosphates to pyruvate is inhibited by PPA along with 6phosphogluconate dehydrogenase being inhibited

(16).

A

general reduction of glucose utilization in liver and brain
induced by the BCKU and PKU metabolites is also shown (l6,
30,44).

It would appear that from these observations the

normal operation of anaerobic oxidation is also impaired by
the BCKU and PKU metabolites.
It is still unknown what the tissue concentrations of
the PKU and BCKU metabolites are in an acute seizure.

In

the untreated, nonconvulsive patients the metabolic levels
in plasma and urine are in the ranges of 0.1 to 10 mM (1,2,

3).

The studies discussed above have generally employed

metabolite levels within this range in their in vitro ex
periments.

The diverse tissue preparations used (perfu

sions , slices, homogenates, whole mitochondria, frozen and
thawed mitochondria, and sonicated mitochondria) in these
studies do not lend themselves to immediate or uncomplicat
ed interpretations of the situation in vivo.

A prime

example of this confusion can be seen when comparing rela
tive tissue pyruvate levels in experimentally induced PKU
in rats and relative plasma pyruvate levels in two PKU
patients.

In the experimentally induced PKU, the pyruvate

levels in brain and liver were reduced 50% and 20% respec
tively (30)-

The plasma pyruvate levels in the PKU patients

were twice that of the controls (42).

The decreased pyr

uvate levels in the PKU patients could be accounted for
by the inhibition by PPA of pyruvate carboxylase (20,42,4*7),
pyruvate decarboxylation (18 ,23), and lactate dehydrogenase
(21,51)*

The contradictory results of these reports are

not readily reconciled and nor can the results of the stud
ies employed explain the disparate pyruvate levels observed.
It may be that in the experimental PKU the phenylalanine
level may not have approached the threshold level neces
sary to be transaminated to PPA,

The plasma concentration

of phenylalanine required for transamination to occur is
0,5 mm (3 ).

There were no plasma phenylalanine concentra

tions given for the induced PKU study but the liver and
brain levels were 3*33 and 0,051 ramol/g tissue, respective-

ly.

These values may he roughly translated into 3.33 mM

and 0.051 mM by assuming that one gram of tissue is approx
imately equal to one milliliter of plasma.

The assumption

clearly places the brain phenylalanine level far below that
required for transamination.

The liver phenylalanine con

centration, by this assumption, is far above that neces
sary for transamination to PPA.

The pyruvate levels in

both tissues were reduced but the level in brain was
depressed far greater than that in the liver.

The phenyl

alanine was injected one hour prior to the sacrifice of the
rats and there may not have been sufficient time for trans
amination to produce the amount of PPA required to inhibit
the pyruvate utilizing enzyme in the liver to elevate the
pyruvate level to that reported for the PKU patients.

The

plasma phenylalanine concentration in the PKU patients
was ^ mM and was sufficiently high enough for transamina
tion to PPA.
This suggests that in PKU the metabolic aberrations
occur on two levels which are dependent on the plasma
phenylalanine concentration.

When the phenylalanine level

is below 0.5 mM, key glycolytic enzymes may be inhibited
and the developing brain is deprived of its energy from
glucose.

A dietary load of protein could send the plasma

phenylalanine
tion to PPA.

above 0.5 mM and begin its transamina
The PPA could then inhibit the primarily

mitochondrial synthetic reactions and oxidative energy
metabolism (see Table 1).

A similar mechanism may be
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operating in BCKU also.

The Michaelis constants (Km) of the

substrates of the branched-chain amino acid transaminase
isozyme I responsible for the majority of the branched-chain
amino acid transamination are about 1 mM (65).

The tissue

concentration of the branched-chain amino acids is on the
order of 0.1 mM (66).

In order for appreciable transamina

tion to occur, the level of branched-chain amino acids must
be elevated at least ten-fold, as in BCKU.

Elevated branch

ed-chain amino acids at concentrations below the Km of the
transaminase may be responsible for the chronic or irrevers
ible biochemical abnormalities in BCKU while the branchedchain a-ketoacids that accumulate when branched-chain amino
acid levels are elevated to concentrations in excess

of the

Km of the transaminase could spark the acute or reversible
symptoms of BCKU,
The evidence that the metabolism of the branched-chain
amino acids is controlled, at least in part, at the level of
transamination is substantial (65).

It is also evident that

phenylalanine metabolism is regulated by its transamination
(3).

It is tempting to speculate, as above, that the chronic

and acute (irreversible and reversible) symptoms observed in
PKU and BCKU are the result of amino acid and a-ketoacid
levels controlled by specific transaminases.
The continuing interest in the defective energy
metabolism in BCKU and PKU and the seemingly contradictory
evidence concerning the effects of the disease metabolites
on pyruvate oxidation lead Land and Clark to suggest that
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there may he an impairment of mitochondrial pyruvate per
meability (29).

The existence of a specific mitochondrial

pyruvate transporter had been proposed earlier by Papa et
al. (67) but the proof of its existence was delayed due to
the lack of a specific inhibitor of pyruvate transport.
Using oc-cyano-4— hydroxycinnamate (CHC) (see Figure 3)1
Halestrap and Denton demonstrated inhibition of pyruvate
transport mitochondria and erythrocytes (68).

Further

evidence supporting the existence of a pyruvate transporter
was soon forthcoming (38 ,39 ,4-0,69,70.72,7*0 .

Data regard

ing the kinetic and exchange properties of the pyruvate
carrier suggest that it should be more generally called the
monocarboxylate transporter as the system was shown to be
responsible for the transmembrane relocation of p-hydroxybutyrate (32*38,55,70), PPA (38 ), acetoacetate (55*70),
lactate (39,70,73). KIC (38,4-0), and KIV (4-0).
Accompanying the elucidation of the function of the
monocarboxylate translocase, were reports that the various
BCKU and PKU metabolites inhibited mitochondrial pyruvate
influx and efflux.

Halestrap and his colleagues observed

that PPA and KIC inhibited pyruvate transport in liver and
brain mitochondria (31,38,71,73)*

Other investigators have

also demonstrated the inhibition of pyruvate exchange in
mitochondria by MSUD and PKU metabolites (39*^0,4-5,4-6,55*

69).

Mitochondrial transport of p-hydroxybutyrate has also

been shown to be inhibited by PPA and KIC (4-5)*

These ob

servations of inhibition of pyruvate and P-hydroxybutyrate

transport were interpreted as being the cause of the di
minished oxidation of these substrates by PPA and KIC (11,
15»29,31 132»^5»50» 69 »71)•

This interpretation was gener

ally accepted in consideration of the apparently conflic
ting data concerning the inhibition of the pyruvate
dehydrogenase complex by PPA and KIC previously discussed.

STATEMENT OF PROBLEM

In order to examine the phenomenon of the inhibition
of pyruvate transport and its relationship to the patho
genesis

of PKU and BCKU, the isolation and purification

of the translocase complex was attempted.

The isolation

of a membrane-free monocarboxylate translocase would obviate
the need for the involved pyruvate transport assay,

A

simple assay for pyruvate binding and the subsequent effects
of the PKU and BCKU metabolites on the binding could be
performed by equilibrium dialysis.

Affinity chromatography

was chosen as the method of isolation.

The ligand attached

to the agarose matrix was CHC, the pyruvate transport
inhibitor (For preparation of the affinity gel, see Appendix
2).

Mouse liver mitochondria, disrupted by either

digitonin or Triton X-100, were applied to the CHC column
and nearly all of the protein was recovered in a single
peak.

Addition of high concentrations of pyruvate or CHC

to the elution medium did not remove any additional protein
from the column.

This indicated that the translocase was

either not bound to the column or had been denatured in
some manner on the gel or prior to its application on the
column.

At that same time, it was reported that the bind

ing of CHC to the translocase was highly transient and
could not be stabilized by ultraviolet light and oxidizing
or reducing agents

(?6).

This indicated that the trans-

locase probably would not bind to the CHC affinity chroma
tography column.

Thus, this line of investigation was

considered futile and was promptly abandoned.
While the BCKU and PKU metabolites were shown to be
competitive inhibitors of pyruvate transport, it was also
noted that they were also transported across the mitochon
drial membranes (38»39»40,55).

Once having gained entry

into the mitochondrial matrix, these ketoacids may adverse
ly affect the metabolic systems contained in that metabolic
compartment.

Using an improved technique, Paradies and

Papa (40,55) demonstrated that PKU and BCKU metabolites
were not as effective as inhibitors of pyruvate transport
as originally reported by Halestrap {31 ,38).

Straight-

chain ketoacids (a-ketobutyrate, a-ketovalerate, a-ketocaproate and acetoacetate)-were more potent inhibitors
of pyruvate transport than the branched-chain and aromatic
a-ketoacids found in BCKU and PKU (40,55)-

Consideration

of the facts that the BCKU and PKU a-ketoacids are capable
of entry into mitochondrial matrix and they are less potent
inhibitors of pyruvate transport than originally surmised
indicates that while inhibition of pyruvate transport
is undoubtedly a contributing factor in the etiology
of the abberrant metabolism observed in the diseased
states, it may not totally account for all of the bio
chemical deficiencies amassed in Table 1.

The carbohydrate

utilization studies of Gibson and Blass showed that the
disease metabolites reduced the production of ^ C O g
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glucose or [2- ^ 0] pyruvate more than that

from

from El-^C] pyruvate (kk).

They also reported that the

activity of the <x-ketoglutarate dehydrogenase complex was
inhibited to a greater extent than pyruvate dehydrogenase
complex.

They interpreted these data as an indication

that the primary action of the a-ketoacids is on the Krebs
cycle at some point other than the pyruvate dehydrogenase
1^
complex. The differential production of
CO2 from the
variously labelled pyruvates implied that the inhibition
of pyruvate transport and pyruvate dehydrogenase complex
were minor effects, as suggested by the work of Paradies
and Papa mentioned above,

Gibson and Blass further sur

mised that there must be more than one reaction of the
Krebs cycle affected in the diseased state since acetylCoenzyme A derived from either [2-^c]pyruvate or [u- ^ c ]
glucose must pass through the complete cycle at least
once before being oxidized to

.

Using electron microscopy, Bowden et al.

have observed

disruption of mitochondrial membrane integrity in the
presence of O.lmM KIC and PPA (36,37)*

To investigate

the effects of this membrane disruption by PPA and KIC
on a mitochondrial enzyme system and simultaneously examine
the possiblility that more than one Krebs cycle reaction
is affected in PKU and BCKU, a study of the effects the
PKU and BCKU metabolites on the oxidation of succinate
oxidase system was undertaken.

The succinate oxidase

system (succinate*ubiquinone oxidoreductase) is known to be
Complex II of the four electron transport complexes (78,79,
80,81,82).

The protein components of Complex II are suc

cinate dehydrogenase (EC 1.3.99.l) and cytochrome
in a 1*1 ratio.

^

The succinate oxidase system is bound to

the inner surface (matrix side) of the inner mitochondrial
membrane.

Thus, succinate dehydrogenase is the only mem

brane-bound Krebs cycle enzyme and as such is well suited
to the proposed line of investigation.

The polarographic

measurement of succinate oxidation in whole mitochondria
permits the determination of several respiratory parameters
(83).

The oxygen consumption rates in the various mito

chondrial metabolic states as defined by Chance and
Williams can be measured (84-).

The five different meta

bolic states are characterized in Table 2 in terms of the
available respiratory substances and the respiratory rates
in the presence of excess inorganic phosphate (Pi).

The

mitochondrial respiration rates of interest in this study
are those of State 3 and State

In State 3* the maximum

oxygen consumption rate is obtained and the only limiting
factor is the availability of the electron transport
tem.

sys

Adenosine diphosphate (ADP) is the rate-limiting

compound in State A respiration where the oxygen consump
tion rate is considerably reduced in comparison to that of
State 3*

State 3 is a condition wherein active respiration

is occurring and ADP is being phoBphorylated concomitantly
with oxygen consumption by the electron transport chain.

TABLE 2
The Mitochondrial Respiratory State Characteristics According to Chance and Williams(8^).

State

Oxygen
Level

ADP
Level

Substrate
Level

Respiration
Rate

Rate-limiting
Factor

1

greater than zero

low

low

slow

ADP

2

greater than zero

high

zero

slow

substrate

3

greater than zero

high

high

fast

respiratory chain

4

greater than zero

low

high

slow

ADP

5

zero

high

high

zero

oxygen

rvj

ro

State k is a "resting" state induced by the depletion or
lack of the phosphate acceptor, ADP.

This regulation of the

respiratory rate by ADP has been called respiratory control
but is now more correctly known as acceptor control since
the respiratory rate is determined by the presence of the
phosphate acceptor (8l).

The degree or extent of acceptor

control is given by the acceptor control ratio (ACR).

The

ACR is defined as the ratio of the State 3 respiratory
rate to the State ^ respiratory rate immediately following
that State 3 period(85).

Whole mitochondria whose ADP

phosphorylation is intimately associated with the electron
transport involved in substrate oxidation are said to be
tightly coupled.

Tightly coupled mitochondria characteris

tically exhibit high ACR's and high P/0 ratios (molecules
of Pi per atom of oxygen consumed during ADP phosphoryla
tion ) (81).

A high ACR is a more rigorous demonstration

of mitochondrial integrity than is the efficiency of oxi
dative phosphorylation as measured by P/0 ratios.

It

has been shown that high P/0 ratios may be observed in
mitochondria with low repiratory control (81,86).

An

estimate of the efficiency of oxidative phosphorylation
can be determined from the ratio of ADP added to initiate
State 3 respiration to the oxygen consumed during State 3»
This quantity known as the ADP/O ratio is equivalent to
the classical P/0 ratio (87).
The respiratory parameters discussed above will be
determined for the succinate oxidase system from mouse liver

mitochondria in the presence and absence of the BCKU and
PKU metabolites.

Liver was the tissue of choice for this

study as liver mitochondria are easier to prepare and liver
cells

contain more mitochondria than brain cells. (81,86).

Also, considerable data on the effects of the PKU and BCKU
a-keto-acids on brain respiration has been reported while
very little information is available on their involvement
in liver metabolism#

It is known that liver ketone body

levels and gluconeogenesis are disturbed by PKU and BCKU
metabolites(16,*4-2,Ml,51) «

An impairment in the sources

of energy available from the liver for the developing and
adult brain could be a partial explanation for the reduced
myelination during the development and subsequent seizures
observed in PKU and BCKU.

The effects of the disease meta

bolites on the structure and metabolism of liver mitochon
dria as measured by the respiratory parameters of the
succinate oxidase system may be useful in elucidation of
the etiology of these similar inborn errors of metabolism.

EXPERIMENTAL PROCEDURES

A.

Reagents
The chemicals employed in this work were of reagent

quality or better and were used without further purification.
The sucrose and potassium hydroxide (KOH) were products of
Mallinckrodt chemical works.

Matheson, Coleman, & Bell

Manufacturing Chemists produced the succinic acid and
L -(-)- tyrosine.

The urea, sodium hydroxide (NaOH), and

sodium chloride (NaCl) were products of Fisher Scientific
Co.

Merck & Co. produced the copper sulfate (CuS0/j.*6H20) .

The sodium potassium tartrate (NaKC^H^O^'^HgO), magnesium
chloride (MgCl2 *6H2), monobasic potassium phosphate (KHgPO^),
and dibasic potassium phosphate (KgHPO^) were products of
J. T. Baker Chemical Co.

Tyrosinase (polyphenol oxidase;

Grade III), 0 -NADH (yeast;Grade III), cytochrome c (equine
heart; Grade III ), ADP (equine muscle; Grade I), BSA (Cohn
Fraction V; 96-99$ albumin), Triton X-100, HEPES, EGTA, KIC,
KMV, KIV, and PPA were obtained from Sigma Chemical Co.
Aldrich Chemical Co. supplied the a-cyano-^-hydroxycinnamic
acid (CHC).

U. S. Industrial Chemicals Co. produced the

absolute ethanol.

All water used was charcoal filtered

and deionized on a mixed-bed resin supplied by Continental
Water Co. and then distilled in all-glass still.
B.

Solutions
The preparation of all solutions is given in Appendix 3»
25
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The standardization of the ADP, NADH, and tyrosine solutions
is given in Appendix
C.

Isolation of Mouse Liver Mitochondria (MLM)
The mice used as a source of mitochondria were the C-^

strain obtained from Sprague-Dawley.

They were maintained

on a 12 hour light and dark cycle with free access to Purina
Laboratory Chow and tap water.

The isolation technique

used is a modification of the preparations of Johnson and
Lardy (86) and Chappell and Hansford (88).

Adult mice of

either sex were sacrificed by cervical dislocation, decapi
tated, and exsanguinated.

The livers were quickly removed

and placed in ice-cold MLM isolation medium (see Appendix 3)
after the removal of the gall bladders.

From this point,

all operations were performed on ice or at
cold solutions and implements.

C using ice-

The livers were blotted,

weighed, and scissored into small pieces in MLM isolation
medium.

The bloody solution was decanted, more MLM medium

was added, and the liver pieces were minced a second time.
After decanting the liquid, the minced liver was homogenized
in 9 volumes (9 x liver weight) of MLM isolation medium with
6 manual passes of an all-glass Dounce homogenizer (0.100.15 mm clearance).

The homogenate was centrifuged in the

SS-34 rotor of a Sorvall RC-2B centrifuge at 2000 revolutions
per minute (rpm)(^80 x gravity) for 10 minutes.

The super

natant was carefully decanted and recentrifuged at 10,000
rpm(12,000 x gravity) for 10 minutes.

The supernatant was

discarded along with the pink ’'fluffy layer” of microsomes
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on the top of the tan mitochrondrial pellet.

The pellet

was resuspended with a glass stirring rod and the suspension
was diluted to one half of the original homogenate volume
with MLM isolation medium and then dispersed with a PotterElvehjem homogenizer with a Teflon pestle (0.10-0.15 mm
clearance).

The suspension was centrifuged at 10,000 rpm

for 10 minutes and the supernatant was discarded along with
the "fluffy layer" as before.

The pellet was resuspended

in one quarter of the original homogenate volume with MLM
isolation medium and again dispersed with the Potter Elvehjem homogenizer.

This second suspension was centrifuged

at 10,000 rpm for 10 minutes and the supernatant and "fluffy
layer" (if any) were discarded.

The pellet was resuspended

and dispersed in a volume of MLM isolation medium equal to
the original weight of the livers.

The dark brown "button"

adhering to the bottom of the centrifuge tube following each
high speed (10,000 rpm) centrifugation was not resuspended
with MLM since this results in mitochondria with lower
rates of oxygen consumption.

This preparation takes about

l£ hours to complete and averages about 19 mg protein/ ml.
This procedure incorporates HEPES into the MLM isolation
medium.

HEPES has been shown to be a superior buffer for

the isolation of mitochondria (89) and for the determination
of mitochondrial respiratory parameters (89,90).

EGTA is
2+
also included in the MUW isolation medium to chelate Ca
ions.

EGTA is preferred to EDTA in that EGTA does not

extract Mg

2+

ions from the mitochondrial membranes and
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making them leaky to K*- ions (88).

Ca^+ ions should he ex

cluded from the isolation and assay media as they uncouple
oxidative phosphorylation and cause a loss in acceptor con
trol (81,91).
D.

Protein Determination
Mitochondrial protein was determined hy a modified

biuret method (92) since the HEPES buffer interferes with
the Lowry protein assay (93)*

To four samples of 0.1 ml of

the mouse liver mitochondrial preparation were added 0.1 ml
of Triton - urea reagent and water to a total of 1.5 ml.
Biuret reagent (1.5 ml) was added to three of these samples
and 1.5 ml of 3$ sodium hydroxide was added to the fourth
to provide a blank.

Standard protein (BSA) and water blanks

were run simultaneously in a like manner with the unknowns.
All samples were incubated for JO minutes at 37° for full
color development.

The absorbance of each sample* standard,

and blank were measured on a Beckman DB spectrophotometer
at 5^0 nanometers.

The biuret standard curve constructed

for this work is given in Appendix 5•
E.

Oxygen Determination
The oxygen content of the succinate oxidase assay

medium was determined by two separate titration methods.
The first method employed the NADH titration (9^) of oxygen
via the electron transport chain of saline-washed mitochon
dria in the presence of cytochrome c (95)•

Mouse liver

mitochondria were prepared as described above and were
resuspended in 10 ml cold water.

This suspension was kept
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at

C for 2 hours and then centifuged at 10,000 rpm for

30 minutes.

The pellet was resuspended in 10 ml of cold

0.9# NaCl and recentrifuged at 10,000 rpm for 10 minutes.
The pellet was taken up again in the saline and centrifuged
as before.

The saline-washed particles were resuspended in

succinate oxidase assay medium such that 1 ml of the suspen
sion represented 1 gram (wet weight) of tissue.

To 1.9 ml

of succinate oxidase assay medium that had been air- satur
ated at 37° C, was added 0.1 ml of saline-washed mitochon
dria, and 25 |il of 1 (iM cytochrome c in the reaction
chamber maintained at 37° •

oxygen in the reaction mix

ture (2.0 ml) was titrated by the addition of four 10 |il
aliqots of 0.0197 M NADH.

The oxygen consumption was meas

ured with a Clark oxygen electrode (Yellow Springs Instru
ment Co.) polarized to 0.8 V and attached to a Gilson Model
KM oxygraph.

Each addition of NADH produced a pen deflect

ion on the oxygraph recorder which was directly related to
to the oxygen content of the solution through the following
relationships
ng-atom 0

net deflection/reaction
-

reaction

1 ng-atom 0
x

average deflection/addition

x

1 nmol NADH

197 nmol NADH
addition
The second method utilized the tyrosinase reaction to
titrate the oxygen content of the reaction volume with L-(-)
-tyrosine.

To 1.9 ml of succinate oxidase assay medium that

had been air-saturated at 37° C, was added 0.1 ml of tyro
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sinase solution in the reaction vessel maintained at 37° 0.
The oxygen in the reaction mixture (2.0) was titrated by
the addition of three 50|il aliquots of 0.00201 M tyrosine.
The consumption of oxygen was followed as described for the
previous method and the oxygen content calculated from the
following relationship that accounts for the different
stoichiometry involvedi
ng-atom 0

net deflection/reaction

4 ng-atom 0
x

reaction

average deflection/addition
101 nmol tyrosine
111
addition

x

1 nmol tyrosine

•

The standardizations of the NADH and tyrosine solutions
employed in these procedures are given in Appendix
F.

Succinate Oxidase Assay
Succinate oxidase activity was determined following the

rate of oxygen consumption with the Clark electrode and
Gilson oxygraph assembly described above.

The 2 ml reaction

chamber, maintained at 37° C, was equipped with ground glass
closure supplied with a small aperture to allow for the add
ition of reagents to the chamber without introducing any
additional oxygen.

Various amounts of assay medium (to

allow for the addition of various other reagents), the suc
cinate or succinate and disease metabolite solutions were
added to the reaction vessel.

The 100# and 0# oxygen levels

on the oxygraph were adjusted with appropriate controls and
0,1 ml mouse liver mitochondria was added to the reaction
mixture and the chamber was closed.

Soon (30-^0 sec) after
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the addition of mitochondria, State 3 oxidation was initiat
ed with the appropriate addition(s) of 0.00925 M ADP with a
Hamilton syringe.

For some experiments, the metabolites un

der investigation were added during State ^ following con
sumption of the first addition of ADP.

Additional aliquots

of ADP was added until the oxygen was depleted.
G.

Data Analysis
By extending the tracings produced by the oxygraph

during each mitochondrial respiration state, the oxygen con
sumption rate of the succinate oxidase system could be
calculated from the tangent of the angle (0)

the extended

lines made with the bottom of the recorder paper as shown
in Figure 4-. It

is also

necessary to measure thetotal

pendeflectionbetween the 100$ and

0$ oxygen levels as

this quantity is proportional to the total oxygen available.
The oxygen consumption rates for the succinate oxidase sys
tem in States 3 and ^ are obtained from the following rela
tionships
reaction rate =

tan 6
chart speed
----------------x ---------------pen deflection
MLM volume

x

oxygen content
protein concentration
Calculation of the ADP/0 ratio, requires that the State 3
oxygen uptake be known.

This value is found, as shown in

Figure 4, by measuring the deflection from the initiation
of State 3 to the beginning of State 4.
calculated as followsi

The ADP/0 ratio was
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Figure 4.

Oxygraph Tracing Depicting the Extraction of

Data for the Computation of MLM Respiratory Parameters.
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nmol ADP added
ADP/0

=
State 3 pen deflection
x

ng-atoms 0

total pen deflection
The succinate oxidase respiratory parameters were calculated
from the oxygraph data using the LSU IBM 360/65 computer
with the FORTRAN program given in Appendix 6.

RESULTS

A. Oxygen Determinations
The titration of the Oxygen content of the 2.0 ml suc
cinate oxidase assay mixture at 37° C by NADH produced a
value of 790 ± 2 (mean + standard deviation) ng-atoms

(198 pM) oxygen from nine determinations.

The five tyrosine

determinations gave a value of 80^ + 1 (mean + standard
deviation) ng-atoms (201 pM) oxygen.

The average of the

results from the two methods is 797 ng-atoms (199 pM) oxy
gen.

This average value is identical to that reported by

Chappell in his NADH titrations of dissolved oxygen (9*0*
The concentration of oxygen in air-saturated water at 37° C
is 225 pM (96).

As expected, the concentration of oxygen

in succinate oxidase assay medium containing 0 .25 M sucrose
is lower than that of water alone since the solubility of
dissolved gases decreases with the amount of solids in solu
tion (97)-

The average value of 797 ng-atoms of oxygen will

be used as the amount of oxygen dissolved in the reaction
volume as its concentration corresponds to that reported by
Chappell (9*0 ■
B.

Succinate Oxidation Baseline Parameters
Immediately following the isolation of the mouse liver

mitochondria, their integrity was verified by a demonstra
tion of acceptor control of the oxygen consumption rates.
Each mitochondrial preparation was subjected to three or
3^
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four determinations of acceptor control by three additions
of 185 nmol of ADP during State 4 respiration as shown in
Figure 5*

Visual verification of an increase in oxygen

consumption upon the addition of each aliquot of ADP was
considered to be a sufficient demonstration of acceptor
control.

Calculation of the respiratory parameters at the

conclusion of the experiment confirmed the validity of this
practice.

The composite values (mean + standard deviation)

for these determinations are as follows* State 3 oxidation
rate, 251 ± 29 ng-atoms o/min/mg protein; State 4 oxidation
rate, 99.0 + 9*3 ng-atoms o/min/mg protein, ACR, 2.57 ± 0.42;
and ADP/0, 1.62 + 0.20.

These values are comparable to

those reported in the literature.

If it was found that a

particular mitochondrial preparation did not have an ACR of
at least 2.0, the data obtained from that preparation was
not used as this is the minimum acceptable level for tightly
-coupled mitochondria oxidizing succinate (86).
C.

Effects of PPA and KIC on Succinate Oxidation Initiated

bv Additions of 186 Nanomoles of ADP
In this series of experiments, succinate or succinate
plus KIC or PPA were added to the assay buffer prior to the
MLM.

Following the addition of the MLM, 185 nmol aliquots

of ADP were introduced into the reaction mixture to produce
three State 3 - State 4 cycles as shown in Figure 5conditions were as previously described.

Other

The effects of

PPA on succinate oxidation initiated by three additions of
185 nmols of ADP as described in Figure 5 are given in
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BUFFER,
SUCCI NATE,
MLM

ADP
(| 8 5 nmol)

ADP
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ADP
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111 n g - a t o m s 0

I min
Figure 5»

Oxygraph Tracing Showing the Initiation of

State 3 Succinate Oxidation by Three Additions of
185 Nanomoles of ADP.
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Table 3.

The State 3 respiration rate was not significantly

reduced by 7.5 mM PPA.

The State ^ respiration rate was

increased by 2Q%>, thus causing a reduction of the ACR by
23.2%.

The ADP/O ratio was reduced by 19-9% in the presence

of PPA.

Under the same conditions, as shown in Table

7*5

mM KIC had no appreciable effect upon succinate oxidation.
By conditioning the mitochondria with a 185 nmols addition
of ADP before adding the KIC as shown in Figure 6, effects
on succinate oxidation could be observed.

For the controls,

assay medium was added following conditioning.

In Table 5

it can be seen that with conditioned mitochondria, there
was no significant reduction in the State 3 respiration
rate, but the other parameters were affected in the same
manner as the unconditioned mitochondria by PPA,

The State

k respiration rate was elevated lk% which lowered the ACR
by 26.3%.
D.

KIC reduced the ADP/O ratio by ?,k%,

Effects of PPA and KIC on Succinate Oxidation Initiated

bv ^63 Nanomoles of ADP in Conditioned Mitochondria
The mitochondria were conditioned by the addition of
185 nmols of ADP prior to the initiation of State 3 oxida
tion with ^63 nmols of ADP as shown in Figure 7*

The con

trols were treated in a like manner with an equal volume of
assay buffer.

The increased amount of ADP used to initiate

State 3 oxidation produced an increase in the control values
for the State 3 respiration and thus the ACR*s.

These in

creases are evident from the comparison of the control
values from Tables 3 and ^ with those of Tables 6 and 7«

TABLE 3
The Effects of PPA on Succinate Oxidation Initiated by 185 Nanomoles of ADP*
Control

PPA

# Control

t-test**

258 + 13

236 + 12

91.5

NS

123 + 5

148 + 18

120

S

Acceptor Control Ratio

2.07 + 0.16

1.59 ± 0.17

76.8

S

ADP/O Ratio

l.kl ± 0.19

1.13 + 0.03

80.1

S

State 3 Respiration Rate
(ng-atoms O/min/mg protein)
State ^ Respiration Rate
(ng-atoms O/min/mg protein)

* pH

37°C, 7*5 mM succinate, 7*5 mM PPA

** 95# confidence level from Student's t distributions
NS - no significant difference; S - significant difference

TABLE 4
The Effects of KIC on Succinate Oxidation Initiated by 185 Nanomoles of ADP*
Control

KIC

# Control

t-test**

251 ± 10

252 + 16

100

NS

99.9 ± 6,1

110 + 11

110

NS

Acceptor Control Ratio

2.57 + 0.14

2.38 + 0.28

92.6

NS

ADP/O Ratio

1.58 + 0,07

1.46 + 0.09

92.4

NS

State 3 Respiration Rate
(ng-atoms o/min/mg protein)
State 4 Respiration Rate
(ng-atoms O/min/mg protein)

*pH 7 .4, 37°C, 7.5

succinate, 7-5 mM KIC

**NS - no significant difference at the 95# confidence level from Student's
t distributions
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BUFFER +
SUCCINATE
ML M
ADP
(l85nmol)

(Q!K A)
ADP
(l85n m o l)

ADP
(185 n m o l)

ADP
(excess)

116 ng-atoms 0

Figure 6.

Oxygraph Tracing Showing the Conditioning of the

Mitochondria by 185 Nanomoles of ADP Prior to the
Addition of the a-Ketoacids.

TABLE 5
The Effects of KIC on Succinate Oxidation
Initiated by 185 Nanomoles of ADP in Conditioned Mitochondria*
KIC

# Control

283 ± 10

273 ± 16

96.5

NS

86.3 ± 4.2

98.7 ± 5-4

114

S

Acceptor Control Ratio

3.32 + 0.11

2.78 + 0.11

83.7

S

ADP/O Ratio

I .63 + 0.06

1.51 ± 0.04

92.6

S

Control
State 3 Respiration Rate

t-test**

(ng-atoms O/min/mg protein)
State 4 Respiration Rate
(ng-atoms o/min/mg protein)

* pH 7.4, 37°C, 7*5 mM succinate, 7*5 mM KIC
MLM were conditioned with an addition of 185 nmols of ADP prior to the
of KIC
** 95# confidence level from Student's t distributions
NS - no significant difference; S - significant difference

addition

kz

BUFFER +
SUCCINATE

Ml7M

ADP
(185 nmol)

(OKA)

\ t ADP
V ( 4 6 3 nmol)

III n g -o t o m s 0

ADP
(excess)

I min

Figure 7.

Oxygraph Tracing Showing the Conditioning of the

Mitochondria by 185 Nanomoles of ADP Prior to the
Initiation of State 3 Oxidation by ^63 Nanomoles of ADP.

TABLE 6
The Effects of PPA on Succinate Oxidation
Initiated by 463 Nanomoles of ADP in Conditioned Mitochondria*
Control

PPA

# Control

t-test**

32k ± 29

260 + 28

80.4

S

87.2 ± 12.3

128 + 8

14?

S

Acceptor Control Ratio

3.72 ± 0.44

2.04 + 0.21

5k. 7

S

ADP/O Ratio

1.61 + 0.09

1.42 + 0.06

88.2

S

State 3 Respiration Rate
(ng-atoms O/min/mg protein)
State 4 Respiration Rate
(ng-atoms O/min/mg protein)

* pH

37°C» 7*5 mM succinate, 7-5 mM PPA

MLM were conditioned with an addition of 185 nmols of ADP prior to the addition
of the PPA
** S - significant difference at the 95# confidence level from Student's
t distributions
'vjO

TABLE 7
The Effects of KIC on Succinate Oxidation
Initiated "by ^63 Nanomoles of ADP in Conditioned Mitochondria*
Control

KIC

% Control

t-test**

338 + 16

3^8 + 17

103

NS

89 .1+ + 5*3-

109 ± 13

122

S

Acceptor Control Ratio

3.79 ± 0.20

3.21 + 0.25

8^.7

S

ADP/O Ratio

1.65 + 0.07

1.51 ± 0.03

91.5

S

State 3 Respiration Rate
(ng-atoms O/min/mg protein)
State ^ Respiration Rate
(ng-atoms O/min/mg protein)

* pH 7-^i 37°C, 7-5 mM succinate, 7*5 mM KIC
MLM were conditioned with an addition of 185 nmols of ADP prior to the addition of
the KIC
** 95# confidence level from Student*s t distributions
NS - no significant difference;

S - significant difference

**5
Table 6 shows the effects of PPA on succinate oxidation in
this system.

PPA decreased the State 3 respiration rate by

19*6# while increasing the State b rate by ^7%.

These

changes are reflected in the ACR which was lowered by ^5*3$
in the presence of PPA.
by 11.8$.

The ADP/O ratio was also decreased

As can be seen in Table 7» KIC had no effect on

the State 3 respiration rate under these conditions.
State 4 respiration rate was increased by 22%.

The

The ACR and

ADP/O ratio were reduced 15*3^ and 8»5$» respectively.
E.

Effects of PPA and KIC on Succinate Oxidation Initiated

bv the Addition of 7^0 Nanomoles of ADP
In this study, the PPA and KIC were added to the assay
medium prior to the introduction of the mitochondria.

Fol

lowing the addition of the mitochondria, a single State 3 State k oxidation cycle was initiated with 7^0 nmols ADP,
as shown in Figure 8 .

Neither PPA nor KIC significantly

affected the State 3 respiration rates and ADP/O ratios as
seen in Tables 8 and 9-

raised the State ^ respiration

rate 39% while KIC increased it 3Q%>»

The ACR's were reduced

by PPA and KIC by 38*7$ and 22.6%, respectively.
F.

The Effects of Increasing PPA and KIC Concentrations

on the Succinate Oxidase Accentor Control Ratios
The ACR's were determined from a series of experiments
in which the PPA concentrations were 0.25 mM, O .63 mM,
2.5 mM, 5»° mM, and 7.5 mM.

State 3 oxidation was initiated

with ^63 nmols of ADP after conditioning and the addition of
PPA as shown in Figure 7*

With increasing concentrations

BUFFER,
SUCCINATE

MLM

± OKA J

ADP
( 7 4 0 nmol)

ng-atoms 0

I min
Figure 8.

Oxygraph Tracing Showing the Initiation of State 3

Oxidation by the Addition of 7^0 Nanomoles of ADP.

TABLE 8
The Effects of PPA on Succinate Oxidation Initiated "by 740 Nanomoles of ADP*
Control

PPA

% Control

t-test**

363 + 24

311 + 34

85.7

NS

84.2 + 7.5

117 ± 7

139

S

Acceptor Control Ratio

4.32 + O .33

2.65 + 0.43

61.3

S

ADP/O Ratio

1.66 + 0,20

1.60 + 0.21

96.4

NS

State 3 Respiration Rate
(ng-atoms O/min/mg protein)
State 4 Respiration Rate
(ng-atoms O/min/mg protein)

* pH 7.4, 37°C, 7-5 mM succinate, 7*5 mM PPA
** 95# confidence level from Student’s t distributions
NS - no significant difference; S - significant difference

TABLE 9
The Effects of KIC on Succinate Oxidation Initiated "by 740 Nanomoles of ADP*
Control

KIC

# Control

t-test**

359 ± 15

359 ± 15

100

NS

84.6 + 4.2

110 + 7

130

S

Acceptor Control Ratio

4.25 ± 0.22

3.29 ± 0.33

77.4

s

ADP/O Ratio

1.59 ± 0.12

1.44 +. 0.09

90.6

NS

State 3 Respiration Rate
(ng-atoms o/min/mg protein)
State 4 Respiration Rate
(ng-atoms O/min/mg protein)

* pH 7.4, 37°C, 7-5 mM succinate, 7-5 mM KIC
** 95# confidence level from Student's t distributions
NS - no significant difference; S - significant difference

of PPA, the ACR's were reduced in a non-linear fashion as
seen in Figure 9» with the majority of the reduction occur
ring below 1 mM,

The effects of KIC at 2.5 mM, 5*0 mM, and

7.5 mM on ACR were determined from the two State 3 “ State b
cycles initiated by 185 nmols of ADP following conditioning
and the addition of KIC as shown in Figure 6.

The ACR’s

for succinate oxidation in the presence of increasing concen
trations of KIC measured in this manner decrease in an al
most linear fashion as shown in Figure 10.

The relative

effectiveness of PPA and KIC in reducing the ACR as their
concentrations are increased is shown in Figure 11 (Care
should be taken in any attempted comparisons of the effects
of PPA and KIC from Figure 11, as the effects of each metab
olite were determined under different conditions).
G.

Effects of Other Compounds on Succinate Oxidation
The other BCKU a-ketoacids (KIV and KMV) and the pyr

uvate transport inhibitor (CHC) did not appear to have any
appreciable effect upon succinate oxidation, based on the
limited data obtained.

Representative data from the use of

these compounds is provided in the computer printout given
in Appendix 6.
H.

Oxygen Consumption by cc-Ketoacids
The a-ketoacids employed in this study did not affect

the oxygen consumption when they were used as substrates
for mitochondrial respiration under the conditions described
Thus, it was not necessary to correct the data to account
for the oxidation of the a-ketoacid.
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Reduction of the Acceptor Control Ratio by PPA.
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Relative Effectiveness of Various Concentrations

of PPA and KIC in Reducing the Acceptor Control Ratio.

DISCUSSION

It has been shown that the initial State 3 mitochondrial
respiration rates are usually less than those observed
following several State 3 - State k cycles (98).

Mitochon

dria may be relieved of this inhibition by incubating
them with substrate and subjecting them to several State 3State 4 transitions with ADP.

Removal of the initial

depression of State 3 respiration in mitochondria has been
termed conditioning (99).

This inhibition is thought to be

a result of the isolation process.

From the data presented

in Tables 3 and 9i it can be seen that there was no effect
upon the State 3 respiration rates in the presence of PPA.
Only when the mitochondria had been conditioned with the
prior addition of ADP did PPA reduce the State 3 respira
tion rate.

This supports the contention of Raison et al.

that the initial inhibition of State 3 respiration must
be removed by conditioning before another type of inhibition
can be observed (98#99)-

Under no conditions employed in

this investigation did KIC affect the State 3 respiratory
rate of either conditioned or unconditioned mitochondria.
This is taken as evidence that PPA is a more potent effector
of mitochondrial respiration than is KIC.
While the effects of KIC on succinate oxidation under
the conditions employed in acquiring the information in
Table ^ were not statistically different from the controls,
53

5h

the presence of the KIC produced a trend sufficiently
analogous to that of PPA to encourage further investigation#
By subjecting the mitochondria to one conditioning cycle
which was not used tn the compilation of the data, the
control values for all four respiratory parameters were
improved,

The State 3 respiration rate was increased while

the State ^ rate was somewhat diminished.

This resulted in

a higher ACR, indicating that the mitochondria were more
tightly coupledo

The increase in the ADP/O ratio meant that

the efficiency of oxidative phosphorylation was enhanced by
the conditioning cycle.

With the improved control values

it was easier to detect changes in mitochondrial respiration
due to the presence of KIC.
It was also stated that two or more State 3 - State 4
cycles using small additions (180 nmols) of ADP were more
effective in overcoming the initial inhibition of State 3
respiration than one large addition (900 nmols) of ADP (98).
This can also be seen when comparing the controls of Table 5
with those of Tables 3 ami

In studies on the effects of

a-ketoacids on pyruvate, P-hydroxybutyrate, and acetoacetate
oxidation in rat brain mitochondria, Clark et al. showed
that one conditioning cycle initiated by 500 nmols of ADP
gave good results when it was followed by a similar addition
after the introduction of the a-ketoacids during the inter
vening State k period (29#32*^5»58).

For the studies

described in Tables 6 and 7 , it was found that a single
conditioning cycle with 185 nmols of ADP also gave good
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control values when it was followed "by an addition of 463
nmols of ADP after the introduction of PPA or KIC during
the intervening State 4 period.

It would appear that there

is more than one way to overcome the intrinsic inhibition
of State 3 respiration imparted to mitochondria by the iso
lation procedure.

In fact, the variation between the iso

lation procedures, the buffer systems employed, and the
source of mitochondria may all affect the magnitude,
duration and measures required to remove the depression of
respiration rates following the isolation of mitochondria.
There are no comparable data from a mammalian system
for that given in Tables 6 and 7*

In this study PPA was

shown to inhibit State 3 succinate respiration by 20$.
PPA (5 mM) has been reported to inhibit State 3 succinate
respiration in yeast mitochondria by 21$, while no inform
ation was provided for State 4 respiration, ACR, or ADP/O
ratios (100).

The study on yeast mitochondria also reported

that CHC (50 pM) and KIC (5 mM) had no effect on State 3
succinate oxidation which is also substantiated by this
investigation in Appendix 6 and Table 7*

As before there

was no information given on the effects CHC and KIC had on
the other parameters of succinate oxidation in yeast
mitochondria.
While the data from Clark’s laboratory regarding the
effects of the BCKU and PKU metabolites on pyruvate,
P-hydroxybutyrate, and acetoacetate oxidation in rat brain
mitochondria cannot be directly compared with the results
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of this study, it is worthwhile to note the similarities
and differences as both investigations are addressing the
same problem.

In rat brain mitochondria oxidizing pyruvate,

2 mM PPA reduced State 3 respiration 55$» had no effect on
State 4 respiration, and reduced the ACR 52$ (^5)*

In the

same system, 2 mM KIC inhibited State 3 respiration 37%,
increased the State ^ respiration rate 28$, and reduced
the ACR 51$.

When tested with rat brain mitochondria oxi

dizing P-hydroxybutyrate, PPA reduced State 3 respiration

36$, increased the State ^ rate 12$, and lowered the ACR
by ^3$•

KIC followed the same pattern as PPA in its effects

on P-hydroxybutyrate oxidation.

The State 3

rate was

inhibited 29$, the State b rate elevated 12$, and the ACR
reduced 36$.

In this study on mouse liver mitochodrial

succinate oxidation, the effects of PPA were not as pro
nounced yet they followed the same trend.

The KIC effects

described in Table 7 for succinate oxidation were not as
great as those reported for the NAD-linked substrates and
KIC evoked no change in the State 3 respiration rate.
In order to ascertain whether or not the initial State

3 inhibition could be overcome by the addition of a large
amount of ADP, studies on the effects of PPA and KIC on
succinate oxidation initiated with ?40 nmols of ADP in
unconditioned mitochondria were undertaken.

As seen in

Tables 8 and 9 the control values for the State 3 respira-r
tion rates were higher than those of the previous studies
and the State 4 rates were lower.

These rates produced the
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highest ACR values reported and the ADP/O ratios were
consistently high also.

It is evident from this information

that the conditioning described above is not necessary for
this particular system.

However, it can be seen from a

comparison of the effects of PPA on conditioned and uncon
ditioned mitochondria that conditioning provides a better
opportunity to observe significant changes in the State 3
respiration rate and the ADP/O ratio.

As for the condition

ing studies described above, there is no similar data
available for comparison with this technique.

The only

other study which employed large quantities of ADP to start
State 3 oxidation was that of Halestrap et al. (31)» where
in the effects of PPA and KIC on rat brain pyruvate oxida
tion are reported.

PPA and KIC were introduced into their

reaction mixture following initiation of State 3 with the
addition of 5000 nmols of ADP/ml.

They reported only that

5 mM PPA and KIC inhibited State 3 oxygen consumption
rates by 57% and 41 fo, respectively.

No details of the

State 3 respirations rates were given and by their method,
no State 4 rates could be obtained.

It is assumed that

their use of such an enormous quantity of ADP was utilized
so as to approximate the State 3 rate thought to occur
in vivo.
In order to determine the sensitivity of the ACR as
a measure of mitochondrial integrity, the effects of in
creasing concentrations of PPA and KIC on the ACR was studied.
Figure 9 clearly shows that the effect of PPA on succinate

oxidation and mitochondrial integrity can be observed at
concentrations below 1 mM.
to be seen at 2.5 mM.

The effect of KIC can begin

These observations are at odds with

the statement of Land and Clark that there was no effect on
succinate oxidation by PPA and KIC in this concentration
range (32).
Again with the saveat that the ACR's were determined
using differing quantities of ADP to initiate State 3
respiration, it may be cautiously inferred from the relative
effectiveness of PPA and KIC in reducing the ACR's of suc
cinate oxidation as shown in Figure 11, that PPA is a more
powerful disruptor of mitochondrial integrity.

This impli

cation is supported by the other information presented in
this investigation.

Under all conditions employed PPA

increased the State 4 oxidation to a greater extent than
KIC and thus reduced the ACR's more than did KIC.

In the

conditioned mitochondria PPA also lowered the ADP/O ratios
more than KIC did and PPA also inhibited State 3 respiration
whereas KIC did not.

It is concluded that this greater

effect upon succinate oxidation by PPA is due to its aro
matic character.

Indeed, aromatic compounds have been

shown to be more efficient inhibitors of mitochondrial oxi
dation than aliphatic ones and this phenomenon has been
attributed to the greater affinity of aromatic compounds to
bind to the hydrophobic sites of the electron transport
system (101).
A final comment on the comparison of the results of
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this work with those of other investigators is in order.
The temperature employed in this investigation was 37° C
while that used in the studies from Clark's laboratory was
25° C (32,^5).

Succinate oxidase activity measured polaro-

graphically exhibits a discontinuity in its Arrhenius plot
in the range of 23-25° C (102).

Discontinuities in the

Arrhenius plot of a membrane-bound enzyme system may be
due to a change in the rate-limiting step of the reaction
it catalyzes or a change in the enzyme conformation due to
a lipid phase transition in the membrane environment of
the enzyme (103»10^).

As the succinate oxidase complex

and the entire electron transport system are integral
membrane proteins, any change in their membrane environment
due to temperature or other factors would be expressed in the
respiratory parameters observed polarographically.

It has

been shown that rat liver mitochondrial membranes undergo
a lipid phase transition from a gel-like solid below 23° C
to a liquid crystalline state above 25° C (10^).

Any

measurements of respiratory characteristics would likely
contain kinetic contributions due to the presence of both
lipid phases in this temperature range.

Interpretation of

data so obtained would have to be done with care and the
extrapolation of any effects observed to a physiological
condition should be made with caution.

The results of the

studies described in this report are free of any complica
tions involved with lipid phase transitions since they
were obtained well above the transition temperature in the

6o
linear region of the Arrhenius diagram.
There are several

implications of the results of this

work that can he related to the general depression of energy
metabolism evident in phenylketonuria and branched-chain
ketonuria.

The inhibition of State 3 respiration by a level

of PPA known to occur in PKU in conditioned mitochondria,
and the trend in that direction in unconditioned mitochon
dria, indicates that electron transport and concomitant ATP
production could be reduced in the diseased state.

The

elevation of State ^ respiration rate by both PPA and KIC
shows that the presence of these compounds allows electron
transport to proceed even in the absence of a phosphate
acceptor.

In other words, PPA and KIC induce a loss of

phosphate acceptor control over electron transport.

This

means that the electron transport system is proceeding with
the reduction of oxygen without any production of metabolically useful energy.

PPA and KIC promote appreciable re

ductions in the acceptor control ratios in conditioned
mitochondria and in unconditioned mitochondria whose State 3
respiration is initiated with a large quantity of ADP (i.e.,
greater than 185 nmols).

As discussed before, the ACR may

be taken as a measure of mitochondrial membrane integrity.
The reduction of the succinate oxidation ACR supports the
suggestion that PKU and BCKU metabolites disrupt internal
mitochondrial structure as observed in electron micrographs
(36,37)-

The reduction in the ADP/0 ratios observed in the

presence of PPA and KIC in conditioned mitochondria shows

6l
that these compounds decrease the efficiency of oxidative
phosphorylation.

The reduced ADP/O ratios demonstrate that

a greater amount of oxygen is being consumed to phosphorylate
ADP' in the presence of PPA and KIC than is normally required.
These effects of PPA and KICT on succinate oxidation are
interpreted as a demonstration that these metabolites which
accumulate in PKU and BCKU act as uncouplers of oxidative
phosphorylation and thus responsible in part for the symp
toms observed.

It would seem that the method

by which the

uncoupling occurs is a direct result of a partial disruption
of inner mitochondrial membrane.

A partially disorganized

inner membrane would then become leaky to protons.

Protons

re-entering the mitochondrial matrix would tend to dissipate
the proton gradient formed by electron transport.

The pro

ton gradient is required by the chemiosmotic theory to pro
vide the driving force for the phosphorylation of ADP to
ATP by F^- ATPase (81,105)i

PPA would further contribute

to the diminution of the proton by inhibiting its formation
by the electron transport system.

From this discussion it

can be seen that the depressed energy metabolism in PKU
and BCKU is, at least in part, due to the lessened effi
ciency of oxidative phosphorylation.

It cannot be stated

that the effects of PPA and KIC seen in these studies are of
a sufficient magnitude to account for all the symptoms ob
served in PKU and BCKU.
In the introductory remarks, it was surmised that the
inhibition of several key mitochondrial transport systems by
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PPA and KIC was a major contributing factor in the diminish
ed energy metabolism in PKU and BCKU.

This does not now

appear to be the case because a reappraisal of the techniques
previously used to measure pyruvate transport was reported
during the preparation of this work.

It was demonstrated

that most of what had been called pyruvate transport was
merely adsorption onto the mitochondrial membrane (106).
The remainder was shown to be pyruvate transport by a modi
fied method and it was also inhibited by CHC.

The inhibi

tion of pyruvate transport by PPA and KIC was shown to be
competition for the nonspecific adsorption sites on the
mitochondrial membrane.

With the new method, PPA and KIC

did not affect pyruvate transport at a concentration of
1 mM.

It remains to be seen whether or not higher concen

trations of PPA and KIC adversely affect pyruvate or any
other monocarboxylate transporter system.
With this new information concerning pyruvate trans
port comes the question of whether or not PPA and KIC are
actually transported across the inner mitochondrial mem
brane as reported earlier (38i39»^0»55)•

There is no evi

dence to preclude the diffusion of KIC and PPA across the
membrane into the matrix space as do acetoacetate and
(3-hydroxybutyrate (106).

It may even be possible for pyr

uvate to enter the mitochondria by diffusion once the
transporter mechanism has been saturated.

It is concluded

that the abnormally high levels of a-ketoacids produced
in PKU and BCKU allow them to inhibit specific enzyme
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reactions involved in energy-related metabolism as well as
to enter the mitochondrial membrane and matrix to partially
uncouple oxidative phosphorylation.

The proposition that

the chronic and acute symptoms of PKU and BCKU are the re
sult of cumulative effects of the diseased-state metabolites
is supported by the wealth of evidence presented in Table 1
and summarized in Figure 12.

The need for another Krebs

cycle reaction to be affected by PPA and KIC (*l4) is satis
fied by the inhibition of citrate synthase (2^,29)»

Figure

12 shows what are considered to be the major common effects
observed due to the presence of the PKU and BCKU a-ketoacids.
Other reactions that are affected by metabolites of either
PKU and BCKU are also shown.

It should be reiterated that

there is no one reaction or metabolic system that is total
ly blocked by the metabolites produced in each genetic
disease.

It is the cumulative effects of the disease-state

metabolites that are considered to produce the clinical
manifestations of PKU and BCKU.

The similarity in the symp

toms observed in both disorders is due to the metabolites
produced by each genetic disorder affecting similar meta
bolic systems.
For normal growth and development, a source of energy,
a source of reducing power, and biosynthetic precursors
are required.
diminished.

In PKU and BCKU the normal levels are all
Energy production is reduced by the reduced

flux of metabolites through glycolysis and Krebs cycle.
This is accomplished through the inhibition of pyruvate
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kinase, pyruvate dehydrogenase, citrate synthase and a-ketoglutarate dehydrogenase.

The reduction of ATP production

due to these inhibitions is further aggravated by partial
uncoupling of oxidative phosphorylation.

The inhibition

of citrate synthase is also responsible for a loss of
reducing power in the form of NADPH.

With the reduction

in citrate production there is a concomitant loss in the
amount of cytosolic isocitrate available for regeneration
of NADPH form NADP by isocitrate dehydrogenase.

The avail

ability of NADPH is further reduced in PKU due to the inhi
bition of 6-phosphogluconate dehydrogenase.

The inhibition

of pyruvate dehydrogenase directly curtails the amount of
acetyl-Coenzyme A available for the biosynthesis of the
lipids required for myelin deposition around nerve tissues.
The level of acetyl-Coenzyme A is also reduced by the inhi
bition of citrate synthase.

The biosynthesis of other

myelin components are also inhibited.

Sterols and long-

chain fatty acids are not produced in sufficient amounts
for normal myelination to occur due to the inhibition of
fatty acid synthase and a deficient supply of energy and
NADPH.

The incorporation of galactose into the cerebrosides

of myelin is also depressed.

The reduction of protein and

nucleic acid synthesis is probably due to the lack of energy
and reducing power.

All these factors are considered to be

contributory to the depressed myelination observed in PKU
and BCKU.

The defective myelination of the nervous tissue

results in the characteristic

mental retardation seen in

phenylketonuria and branched-chain ketonuria.
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APPENDIX 1
Abbreviations

A ..............
AcAC

..........

adrenal
acetoacetate

AcAc-CoA........ acetoacetyl-Coenzyme A
Ac-CoA

........

acetyl-Coenzyme A

ACR ............

acceptor control ratio

ADP ............

adenosine 5*-diphosphate

ADP/O . . . . . .

ADP phosphorylated per oxygen consumed

A L A ............ alanine
A S P ............ aspartate
A T P ..........

. adenosine 5*-"triphosphate

B .............. brain
BCKA

. . . . . .

branched-chain oc-ketoacids

BCKU

..........

branched-chain ketonuria

B 1 .............. blood
BSA ............

bovine serum albumin

C ..............

Celsius

C^gFA ..........

any fatty acid containing sixteen carbons

CHC . . . . . . .

a-cyano-it-hydroxycinnamic acid

C I T ............ citrate
C o A ............ Coenzyme A
E ..............

erythrocyte

EDTA

..........

ethylenediamine tetraacetic acid

EGTA

..........

ethyleneglycol-bis (P-aminoethyl ether)76

N,N'-tetraacetic acid
F^-ATPase . . . .

mitochondrial enzyme phosphorylating
ADP to ATP

F b .......... .. fibroblast
G A L ............ galactose
G L U ............ glutamate
G-6-P ..........

glucose-6-phosphate

H .............. heart
KEPES ..........

N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid

H P A A .......... o-hydroxyphenylacetic acid
I C I T .......... isocitrate
l i e ............ isoleucine
K ..............
aKA .

kidney

......... a-ketoacid

aKG ............

a-ketoglutarate

KIC . . . . . . .

a-ketoisocaproate

KIV ............

a-ketoisovalerate

Km

Michaelis constant

............

KMV ............

a-keto-0-methylvalerate

L .............. liver
........

. . microliter

LAC. . . . . . .

lactate

L b ............ lymphoblast
Leu. . . . . . .

leucine

| i M ............ micromolar
M ............ .. molar (moles per liter)
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M A L ......... malate
MAL-CoA ........

malonyl-Coenzyme A

m g ....... milligram
m i n ......... minute
m l ....... milliliter
MLM ............

mouse liver mitochondria

m m ....... millimeter
m M ....... millimolar
MSUD

. . . . . . maple syrup urine disease (branched-chain
ketonuria)

NAD ............

nicotinamide

adenine dinucleotide,

oxidized form
NADH

..........

nicotinamide

adenine dinucleotide,

reduced form
NADP

..........

nicotinamide

adenine dinucleotide

phosphate, oxidized form
NADPH ..........

nicotinamide

adenine dinucleotide

phosphate, reduced form
n g ........ nano gram
n m o l ...... nanomole

0 ............

. atomic oxygen

O A A ....... ..... oxaloacetate
p-OH-B

. . . . . p-hydroxybutryate

P . . . . . . .

.pancreas

P A A ... phenylacetic acid
P E A .... phenylethylamine
PEP . . . . . . .

phosphoenolpyruvate

6-P-G . . . . . .

6-phosphogluconate

p H ............ negative logarithm of the hydrogen ion
concentration
Phe . . . . . . .
Pi

............

PKU ............

phenylalanine
orthophosphate
phenylketonuria

P L A ............ phenyllactic acid
P/0 ............

phosphate consumed per oxygen consumed

PPA ............

phenylpyruvate

PYR.

......... pyruvate

rpm . . . . . . .
Ru-5-P

........

revolutions per minute
ribulose-5-phosphate

S U C .............. succinate
TRIOSE-P

....

triose phosphate

V a l ............ valine

APPENDIX 2
The Coupling of a-Cyano-4-hydroxycinnamic Acid to Agarose

Fifteen ml bromoacetamidohexylagarose freshly prepared
according to March et al. was washed with 50 ml of 0.1 M
NaHCO^ (pH 9*5)-

The wash solution was removed by suction

and the packed gel was added to 0.2 mole of a-cyano-4hydroxycinnamic acid (CHC) in 20 ml dioxane.

The pH was

adjusted to 9*5 and the reaction was allowed to proceed at
room temperature for 3 days with constant agitation.

The

pH was monitored periodically and readjusted to 9-5 as
nescessary.

After 3 days the dioxane solution was removed

by suction and the gel was mixed with 30 ml of 0,2 M mercaptoethanol in 0.01 M NaHCO^ (pH 9*5) for 2 hours at room
temperature to block any unreacted bromoacetyl groups.
Following the mercaptoethanol treatment, the gel was washed
with 200 volumes of 0.2 M NaCl and then with 200 volumes of
water.

This procedure was patterned after the procedure

employed by Cuatrecasas to link estradiol through its
hydroxyl function to bromoacetamidohexylagarose.
To determine the amount of CHC bound to the agarose,
0.2 ml of the packed gel was solubilized according to the
method of Failla and Santi.

The solubilized CHC-agarose

exhibited a Xmax of 280 nm as compared to that of the free
CHC of 32^ nm.

This spectral shift is indicative of attach

ment through the hydroxyl function of CHC.
80

The amount of

CHC bound was estimated to be 230 nmol/ml of packed gel
using Beer's law and the molar extinction coefficient of
p-methoxycinnamic acid (23 ,7°0 M ^ ) (Sadtler Standard Spec
tra).

The proposed structure of the agarose derivative is

given in Figure 1-A.
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Figure 1-A.

The proposed structure for a-cyano-^-hydroxy-

cinnamic acid-agarose.

APPENDIX 3
Solutions

A.

Adenosine V -Drphosohate (0.0925 M)
One gram of barium ADP was dissolved in a minimum

volume of 0.01 M KPi buffer (pH6 .8) and the barium was pre
cipitated with an equimolar quantity of sodium sulfate.
The BaSO^ precipitate was removed by centrifugation.

The

supernatant was decanted and taken up to 70 ml to give an
approximately 0.1 M ADP solution.

The determination of the

actual 0.0925 molarity is given in Appendix
B.

Biuret Reagent
To 500 ml of water were added 1.5 g of CuS0^‘5H2O and

6.0 g of NaKC^Og'^HgO.

This solution was added to 300ml of

10fo (w/v) NaOH and then made up to 1 liter with water.
C.

Bovine Serum Albumin
One hundred mg of BSA were dissolved in water and made

up to 10.0 ml to give a standard protein solution with a
concentration of 10.0 mg/ml.
D.

q-Cvano-^-hvdroxvcinnamic Acid (0.1 M)
This solution was prepared by taking 0,1892 g of CHC

up to 10.0 ml in absolute ethanol.
E.

Cytochrome c (1.0 11M)
Ten pi of 0,000815 M equine cytochrome c (12,270 dal-

tons) was added to 8 .1^ ml of succinate oxidase assay
medium.
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F.

Disease Metabolite Stock Solutions
Stock solutions of 0.25 M KIC, KIV, KMV, and PPA in

the succinate oxidase assay medium were prepared weekly from
the sodium salts and stored frozen.
G.

3-Nicotinamide Adenine Dinucleotide. Reduced Form

(0.0197 M)
About 15 mg of P-NADH were dissolved in 1 ml succinate
oxidase assay medium to give an approximately 0,02 M {3-NADH
solution.

The determination of the actual 0.0197 molarity

is given in Appendix 4.
H.

Mouse Liver Mitochondria Isolation Medium
The MLM isolation medium was composed of 0.25 M sucrose,

0.001 M HEPES, and 0.001 M EGTA.

The pH was adjusted to 7*4

at 4° C with K0H.
I.

Potassium Phosphate Buffers (0.1 M)
Tenth molar solutions of the monobasic and dibasic

potassium salts were mixed in various proportions to pro
duce the 0.1 M KPi buffers of the required pH values.
J.

Succinate Stock Solution
A stock solution of 0.5 M succinate was prepared in

water from the free acid.

The acid was neutralized and

the pH adjusted to 7.4 with K0H.
K.

Succinate Oxidase Assay Medium
The succinate oxidase assay medium was composed of

0.25 M sucrose, 0,01 M KPi (100 ml of 0.1 M KPi buffer,
pH 7.4 per liter), 0.001 M HEPES, 0.001 M EGTA, and 0.005 M
MgClg.

The pH was adjusted to 7*4 at 37° C with K0H.

L.

Triton - Urea Reagent
Four ml of Triton X-100 were added to 100 ml of satu

rated urea to give a 4# (v/v) Triton - urea solution,
M.

Tyrosinase Solution
Crystalline tyrosinase (2750 units/mg) was dissolved

in succinate oxidase assay medium to yield a solution with
an activity of 10,000 units/ml.

One unit of tyrosinase

causes an increase in absorption at 280 nm of 0 .00l/min
at pH 6.5 at 25°C in a 3^0 ml reaction volume containing
L-(-)-tyrosine.
N.

Tvrdsine (0.00201 M)
L-(-)-Tyrosine was made up in succinate oxidase assay

medium to be approximately 0.002 M.

The determination of

the actual 0.00201 molarity is given in Appendix 4.

APPENDIX k
Assays of Titrant Solutions

A.

Adenosine V

- Diphosphate

Five aliquots of the approximately 0.1 M ADP solution
were diluted $000 fold in 0.01 M KPi (pH

The absorp

tion of these solutions was measured at 259 nm on a Cary l^Jspectrophotometer and their molarities were calculated
using Beer's Law and a molar extinction coefficient of
15,^00 M

.

After correcting for the dilution, the concen

tration of the original solution was determined to be
0.0925 + 0.0001 M (mean + standard deviation) .
B.

g-Nicotinamide Adenine Dinucleotide. Reduced Form
Five aliquots of the approximately 0.02 M NADH solution

were diluted 1250 fold with 0.01 M KPi (pH 7-*0.

The opti

cal density of the dilutions were measured on a Cary 1^
spectrophotometer at 260 nm.
extinction coefficient of 6250

Using Beer's Law and the molar
(taken from the NADH pro

duct brochure supplied by SIGMA Chemical Co.), the molari
ties of the dilutions were calculated.

The concentration

of the original NADH solution was found to be O.OI97 +
0.0002 M (mean + standard deviation) after correcting for
the dilution.
C.

L-(-)-Tvro sine
Five aliquots of the approximately 0.002 M tyrosine

solution were diluted 10 fold in 0.01 M KPi (pH 7»^).
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absorption of these dilutions were determined at 275 nm on
a Cary 1^ spectrophotometer and their molarities were cal
culated using Beer's Law and a molar extinction coefficient
of 1^13 M-'*’.

After correcting for the dilution, the concen

tration of the original tyrosine solution was determined to
be 0,00201 + 0.00002 M (mean + standard deviation).

Appendix 4 References
Robinson, J. W, (ed.) (197*0 Handbook of Spectroscopy,
Vol. II, Chemical Rubber Company, Cleveland, Ohio,
p. 15*1-.
Sober, H. A. (ed.) (1970) Handbook of Biochemistry. 2nd
Edition. Chemical Rubber Company, Cleveland, Ohio,
p. G 60.

APPENDIX 5
Biuret Standard Curve
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APPENDIX 6 *
C01 PROGRAM COMPUTES MLM OXYGEN CONSUMPTION RATES (NANOGRAM-ATOM O/MIN/MG
C

PROTEIN) IN STATES 3 & if-, ACCEPTOR CONTROL RATIO (ACR) & ADP/O

C

RATIO FROM OXYGRAPH DATA.

C

DEVIATION (STD DEV) &

C

MLM PARAMETER.

fo

AVERAGE DEVIATION (AVG. DEV), STANDARD

CONTROL

(fo

CON) ARE CALCULATED FROM EACH

1

DIMENSION S 3 (35.3). S4 (35.3). PO (35.*0. CW (35), ACR (35), ADPO (35)

2

DIMENSION RCR (35.3) AVS 3 (35). AVS^ (35). X (6,4,^,) LL (6), ADP (35.3)
C02

ENTERS TOTAL NUMBER OF DETERMINATIONS & NUMBER OF CONTROL, KIC, KMV,

C
3

READ
C03

k

KIV, PPA, & CHC DETERMINATIONS.
(5,100) M, (LL(I), 1= 1,6)

ENTERS ANGLES OF STATE 3 & 4 TRACINGS, STATE 3 CHART DIVISIONS/ADP

C

CYCLE, MICROLITERS 0.0925M ADP/CYCLE & NET CHART DIVISIONS/

C

DETERMINATION (MAX OF 3 ADP CYCLES/DETERMINATION)
READ
C

(5,110) ( (S3(I,J), SMI.J), PO(I,j) , ADP (I ,J ), J=l,3), CW(I),
I = 1,M)

5

100 FORMAT (715)

6

110 FORMAT (13F5.1)

co^

MILLIGRAMS MLM PROTEIN/DETERMINATION
PROT = 1 . 9 1

7
C05
c

LOOP CALCULATES & SUMS RATES, ACR & ADP/O FOR EACH CYCLE OF EACH
DETERMINATION & DETERMINES DIVISORS FOR COMPUTING AVERAGES.
DO 130 I = 1,M

8
C06

INITIALS AVERAGES TO ZERO.

9

AVS3 (I) = 0.

10

AVS4 (I) = 0.

11

ACR(I )

= 0.

12

ADPO(I)

= 0.

13

DO 120 J = 1,3
CO?

CONVERTS DEGREES TO RADIANS.

14-

S3 (I,J) = S3 (I.J)/57.2957795

15

Sk (I.J) = S4 (I,J)/57*2957795
C08

COMPUTES TANGENT (SLOPE).

16

S3 (I,J) = TAN (S3 (I,J)>

17

(I,J) = TAN (S4(I,J))
C09

COMPUTES OXYGEN CONSUMPTION RATES.

18

S3 (I.J)

= (S3 (I.J) *30 . * 797.V(CW(X) *PROT)

19

S^ (I.J)

= (Sk (I,J) *30. * 797.V(CW(I) *PR0T)

CIO

IF STATEMENTS PROVIDE FOR VARIOUS ADP CYCLES & INCOMPLETE DATA.

20

IF (S3 (I.J). EQ.O.)GO TO Ilk

21

IF (Sk (I,J). E Q .0,)GO TO 115
Cll

22

COMPUTES ACR.
RCR (I,J) = S3 (ItJ)/S^ (I.J)

C12 COMPUTES NANOMOLES ADP CONSUMED/CYLCE.
23

ADP (I,J) = ADP (I,J) * 92.5
C13

COMPUTES ADP/O.
PO (I,J) = (ADP (I,J) * CW(I))/PO

2k
Cl4

SUMS RATES, ACR, ADP/O FOR EACH DETERMINATION.

25

AVS3 (I)

= AVS3 (I) + S3 (I,J)

26

AVS14* (I)

= AVSif (I) +

27

ACR (I) =

28

ADPO (I) = ADPO(I) + PO (I.J)
C15

29

(I.J) * 797A )

(I.J)

ACR(I) + RCR (I.j)

DEFINES DIVISORS FOR 3 ADP CYCLES.
zi

= 3.0

30

Z2 = Zl

31

GO TO 120
C16

32

DEFINES DIVISORS FOR LESS THAN 3 ADP CYCLES.

lib Zl = FLOAT (J-l)

33

Z2 = Zl

3k

GO TO 125
C17

35,

COMPUTES COMPUTATIONS & DEFINES DIVISORS FOR INCOMPLETE DATA.

115 AVS 3 (I) = AVS3 (I) + S3 (I,J)

36

Zl

= FLOAT (J)

37

Z2

= FLOAT (J-l)

38

GO

TO 125

39

120 CONTINUE
C18

kO

AVERAGES RATES, ACR, & ADP/O FOR EACH DETERMINATION.

125 AVS 3 (I)= AVS3(I)/Zl

iR

AVSk (I) = AVS1* (I)/Z2

kZ

ACR (I) = ACR (I)/Z2

k3
kk

ADPO (I) = ADPO (I)/Z2
130 CONTINUE

45

DO 140 I

= 1,6

46

DO 140 j

* 1,4

47

DO 140 K

= 1,4

C19 INITIALS OUTPUT MATRIX TO ZERO FOR SUMMATIONS PRIOR TO AVERAGING
C

DATA SETS.

C

I = DATA SET (CONTROL (l), KIC (2), KMV (3 ), KIV (4), PPA

C

J = PARAMETER DESIGNATIONS

C

(5), CHC (6))

(STATE 3(1), STATE 4(2), ACR (3 ),

ADP/O (4))
K = PARAMETER DATA ( PARAMETER VALUE (1), AVG DEV (2 ), STD DEV (3 ),

C
C
48

MATRIX SUBSCRIPTS (I,J,K) ARE DEFINED AS

% CON (4))
140 X ( I ,J,K) = 0.

49

N = 0

50

L = 0
C20

51

OUTER LOOP GROUPS INDIVIDUAL DETERMINATIONS INTO SETS.
DO 1000 I = 1,6

C21

IF STATEMENT ACCOUNTS FOR LACK OF CERTAIN DATA SETS.
IF (LL(I). EQ.O.)GO TO 1000

C22

REDEFINES INITIAL INDEX FOR INNER LOOPS WITH EACH TURN OF OUTER LOOP
vO

VO

N = L + 1

53
C23

REDEFINES FINAL INDEX FOR INNER LOOPS WITH EACH TURN OF OUTER LOOP.
L = L + LL(I)

54
C24

LOOP SUMS RATES, ACR, & ADP/O FOR EACH DATA SET

55

DO 150 J = N,L

56

X(I, 1 ,1 ) = X(I,1 ,1 ) + AVS3CJ)

57

X(I,2,l) = X(I,2,1) + AVS4(J)

58

X(I,3,1) = X(I, 3 ,1 ) + ACR(J)

59

150 X(I,4,l)

60

= X(I,4,1) + ADPO(J)

Z = FLOAT (LL(I))
C25

LOOP AVERAGES EACH PARAMETER VALUE

61

DO 160 J - 1,4

62

160 X(I,J,1) = X(I,J,1)/Z

63

DO 163 J = N,L

64

DO 163 K = 1,4
C26

65

INITIALS USED DATA STORAGE TO ZERO FOR USE AS TEMPORARY STORAGE.

I 63
C27

PO(J,K) = 0

LOOP CALCULATES ABSOLUTE VALUE OF DEVIATION OF MLM PARAMETERS

66

DO 165 J = N,L

6?

PO (J.l) =ABS(X(I,1.,1) - AVS 3 (J))

68

PO (J,2) = ABS(X(I,2,l) - AVS^(J))

69

PO (J,3) = ABS(X(I,3 ,1 ) - ACR(J))

70

PO (J.ij-) = ABS(X(Ii^,l) - ADPO(J))

71

DO 165 K = 1,1*
C28

72

X(I,K,2) = X(I,K,2) + PO(J,K)
C29

73

SUMS ABSOLUTE VALUES OF DEVIATIONS.

SUMS SQUARES OF ABSOLUTE VALUES OF DEVIATIONS.

165 X(I,K,3) = X(I,K,3) + P0(J,K)**2.

71*

DO 170 J - 1,1*
C30 COMPUTES AVG DEV FOR EACH DATA SET.
X(I»J f2) = X(I,J, 2 )/Z

75
C31
76

X(I,J,3) + SQRT(X(I,J,3)/(Z - i;))
C32

77
78

COMPUTES STD DEV FOR EACH DATA SET.

COMPUTES % CON FOR EACH DATA SET.

170 X ( I tJ,Z*) = (X(I, J ,l)/X(l,J ,l)) * 100.
1000 CONTINUE

C33 OUTPUT MATRIX PRINTED IN TABULAR FORM WITH COLUMN AND LINE HEADINGS.
C
79

80

DATA SET POPULATION PRINTED BELOW COLUMN HEADINGS.
WRITE (6,200)(LL(I), I = 1,6)

200 FORMAT ('O', T15. 'CONTROL', T 27 , 'KIC', T37 , 'KMV', T47, *KIV», T57, 'PPA',
C

T 67 , *CHC'/. ’ ', T 9 , (6 1 10))

81

WRITE

(6,210) ((X(I,1,J), I

= 1,6) J = 1,4)

82

WRITE

(6,220) ((X(I,2,J), I = 1,6) J = 1,4)

83

WRITE

(6 ,230) ((X(I,3 ,J),I = 1,6) J = 1,4)

84

WRITE

(6,240) ((X(I,4,J), I

85

210 FORMAT

= 1,6) J = 1,4)

('O', (T2, 'STATE 3', T13, 6FIO.5/,' ', (T2, 'AVG DEV*, T13,

C 6F10.5)/,

'', (T2,

'STD DEV*, TI 3 ,6FIO.5 )/,' ', (T2,» % CON', T13,

C 6FIO.5 ))

86

220 FORMAT

('O', (T2, 'STATE 4*, TI 3 , 6F10.5)/,' ', (T2, 'AVG DEV*, T13,

C 6F10.5)/,

'

(T2,

'STD DEV',

T13 ,6FIO.5 )/, ' ', (T2, » % CON*, T13,

C 6FIO.5 ))

87

230 FORMAT

('O', (T2 , 'ACR

C 6FIO.5 )/,

**, (T2,

',T13 , 6FIO.5 )/, ' ', (T2, 'AVG DEV*, T 13 ,

'STD DEV', T13, 6F10.5)/,' \

(T2,* % CON', T13,

C 6F10.5))
vO

CN

88

240 FORMAT

('O', T2, ADP/O', T13, 6F10.5)/,'

(T2, 'AVG DEV', T13

C 6FIO.5 )/,' ', (T2, 'STD DEV', T13, 6F10.5)/,'

(T2, ' % CON', TI3,

C 6F10.5))

89

STOP

90

END

$ENTRY
CONTROL
7
STATE 3

KIC
2

KMV
3

KIV
2

PPA
4

CHC
2

264.84440 277.71700 271.22770 294.33830 242.54510 261.11980

AVG DEV

10.29217

2.97229

6.05827

8.01648

10.25576

18.65442

STD DEV

14.46849

4.20345

7.99991

11.33701

12.99591

26.38132

100.00000 104.86030 102.41010 III.I362O

91.58022

98.59364

%

CON

STATE 4

126.15260 151.25580 132.90550 140.99510 151.72610 130.36560

AVG DEV

4.33911

2.71819

2,38438

6.63634

17.37238

11.20471

STD DEV

5.79400

3,84409

3.09853

9.38520

20.10561

15.84585

%

CON

100.00000 119.89900 105.35280 III .76540 120.27180 103.33950

\o
-o

ACR

2.07484

1.81735

2.04018

2.03424

1.59282

2.02291

AVG DEV

0.14020

0.09975

0.02863

0.09779

0.15052

0.02281

STD DEV

0.17^39

0.14107

0.03921

0.13830

0.18266

0.03226

CON

100.00000

87.58969

98.32921

98.04314

76.76819

97.49709

ADP/O

1.40956

1.24891

1.38745

1.40528

1.13233

1.43647

AVG DEV

0.16439

0.08597

0.06752

0.13284

0.02449

0.05047

STD DEV

0.20005

0.12157

0.08928

0.18786

0.03620

0.07138

CON

100.00000

88.60242

98.43095

99.69641

%

%

80.33212 101.90900

*To enhance the legibility of the program, extra spaces were added to the program
statements.

In doing so, some COMMENT, DIMENSION, and FORMAT statements

appear to exceed the ?2 space limitation for punched cards.

This extra

spacing must be taken into account when transcribing the program statements.
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